These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 24324033)

  • 1. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
    Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
    Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-30e-3p Influences Tumor Phenotype through
    Gramantieri L; Pollutri D; Gagliardi M; Giovannini C; Quarta S; Ferracin M; Casadei-Gardini A; Callegari E; De Carolis S; Marinelli S; Benevento F; Vasuri F; Ravaioli M; Cescon M; Piscaglia F; Negrini M; Bolondi L; Fornari F
    Cancer Res; 2020 Apr; 80(8):1720-1734. PubMed ID: 32015093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.
    Fornari F; Milazzo M; Chieco P; Negrini M; Marasco E; Capranico G; Mantovani V; Marinello J; Sabbioni S; Callegari E; Cescon M; Ravaioli M; Croce CM; Bolondi L; Gramantieri L
    J Pathol; 2012 Jul; 227(3):275-85. PubMed ID: 22262409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
    Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
    Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2-p53 pathway in hepatocellular carcinoma.
    Meng X; Franklin DA; Dong J; Zhang Y
    Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
    Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
    Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
    Fornari F; Gramantieri L; Giovannini C; Veronese A; Ferracin M; Sabbioni S; Calin GA; Grazi GL; Croce CM; Tavolari S; Chieco P; Negrini M; Bolondi L
    Cancer Res; 2009 Jul; 69(14):5761-7. PubMed ID: 19584283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
    Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
    J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gα12gep oncogene inhibits FOXO1 in hepatocellular carcinoma as a consequence of miR-135b and miR-194 dysregulation.
    Jung HS; Seo YR; Yang YM; Koo JH; An J; Lee SJ; Kim KM; Kim SG
    Cell Signal; 2014 Jul; 26(7):1456-65. PubMed ID: 24631529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
    Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
    Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53-induced microRNA-1246 inhibits the cell growth of human hepatocellular carcinoma cells by targeting NFIB.
    Zhang Q; Cao LY; Cheng SJ; Zhang AM; Jin XS; Li Y
    Oncol Rep; 2015 Mar; 33(3):1335-41. PubMed ID: 25591821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1.
    Lu L; Zhang D; Xu Y; Bai G; Lv Y; Liang J
    Biomed Pharmacother; 2018 Aug; 104():613-621. PubMed ID: 29803174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCAT2 contributes to hepatocellular carcinoma progression via inhibiting miR-145 maturation to induce MDM2 expression.
    Niu C; Wang L; Ye W; Guo S; Bao X; Wang Y; Xia Z; Chen R; Liu C; Lin X; Huang X
    J Cell Physiol; 2020 Sep; 235(9):6307-6320. PubMed ID: 32037568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An oral 2-hydroxypropyl-β-cyclodextrin-loaded spirooxindole-pyrrolizidine derivative restores p53 activity via targeting MDM2 and JNK1/2 in hepatocellular carcinoma.
    Gao X; Wei M; Shan W; Liu Q; Gao J; Liu Y; Zhu S; Yao H
    Pharmacol Res; 2019 Oct; 148():104400. PubMed ID: 31425749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
    Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
    Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway.
    Huang K; Tang Y; He L; Dai Y
    Oncol Rep; 2016 Feb; 35(2):887-95. PubMed ID: 26718483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop.
    Xia C; Shui L; Lou G; Ye B; Zhu W; Wang J; Wu S; Xu X; Mao L; Xu W; Chen Z; Liu Y; Zheng M
    Sci Rep; 2017 Jun; 7(1):4396. PubMed ID: 28667294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry.
    Simerzin A; Zorde-Khvalevsky E; Rivkin M; Adar R; Zucman-Rossi J; Couchy G; Roskams T; Govaere O; Oren M; Giladi H; Galun E
    Hepatology; 2016 Nov; 64(5):1623-1636. PubMed ID: 27302319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-758-3p suppresses proliferation, migration and invasion of hepatocellular carcinoma cells via targeting MDM2 and mTOR.
    Jiang D; Cho WC; Li Z; Xu X; Qu Y; Jiang Z; Guo L; Xu G
    Biomed Pharmacother; 2017 Dec; 96():535-544. PubMed ID: 29032337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.
    Chen E; Li E; Liu H; Zhou Y; Wen L; Wang J; Wang Y; Ye L; Liang T
    Int J Biol Sci; 2021; 17(3):781-795. PubMed ID: 33767588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.